UPDATE 1-Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan

Reuters2021-04-18

(Adds Pfizer's confirmation of talks with Japan PM, background of COVID-19 in Japan)

By Kanishka Singh

April 17 (Reuters) - Japanese Prime Minister Yoshihide Suga asked U.S. drugmaker Pfizer Inc on Saturday to provide additional supplies of COVID-19 vaccine to Japan this year, Nikkei reported.

Pfizer confirmed in an email that Pfizer CEO Albert Bourla met with Suga virtually to discuss vaccine supply on the last day of Suga's three-day visit to Washington. The Pfizer/BioNTech vaccine is the only one approved in Japan.

Japan's Nikkei newspaper reported earlier that Suga asked Pfizer to provide more vaccine doses.

Inoculations of Japan's sizable elderly population began on Monday, but some experts cautioned that the general population may not have access to vaccination until late summer or even winter because of constrained supplies.

Japan was among the last major economies to begin COVID-19 inoculations when it started in mid-February, after domestic trials to ensure safety.

Only 0.9% of the Japanese public received their first vaccine shot as of Friday, compared with 2.5% in South Korea, and 48% in the United Kingdom.

Japan's top health experts have acknowledged that the COVID-19 pandemic has entered a fourth wave.

Japan has exhibited "poor performance" in containing virus transmission, along with limited testing capacity and a slow vaccination rollout, according to a commentary of health experts published in the British Medical Journal on Wednesday.

Tokyo's Olympics chief said on Friday that Japan was committed to holding a safe Games this summer, as a surge in COVID-19 cases prompted an expansion of contagion controls and with fresh calls for the Games to again be postponed or canceled.

(Reporting by Kanishka Singh in Bengaluru; editing by John Stonestreet and Cynthia Osterman)

((Kanishka.Singh@thomsonreuters.com; +91 8061822801;))

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
2